← Home / Peptides / YourProtocol / PT-141 / Bremelanotide: Evidence and Safety
Peptides Peptides

PT-141 / Bremelanotide: Evidence and Safety

PT-141 (bremelanotide) is FDA-approved as Vyleesi, but only for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT phase 3 trial program. Using it for general “libido enhancement” outside that specific population and indication is off-label and far less studied; the evidence is Tier A only for the approved use.

💊
YourProtocol
YourProtocol Research
In-house · Synthesized from the cited primary sources
Daily time
5 min
Difficulty
Beginner
Sources
1
What the evidence says
What it is

Understand the mechanism

A melanocortin-receptor agonist that acts centrally in the brain on the system that governs sexual desire, unlike PDE5 drugs that act on blood flow.

This is a different mechanism class from erectile-dysfunction drugs, which is why it targets desire rather than blood flow.

FDA approval record; RECONNECT phase 3 program
For this step
No product needed
Evidence tier: A (for its approved use only)

See what the approval actually covers

FDA approved Vyleesi in June 2019 for hypoactive sexual desire disorder (HSDD) specifically in premenopausal women, based on the RECONNECT phase 3 trial program. Off-label use outside that population and indication is far less studied.

Rounding the approval up to general “libido enhancement” misrepresents what the trials actually tested.

FDA approval basis: RECONNECT phase 3 program
For this step
No product needed
Legal status

Know where it stands

FDA-approved (Vyleesi brand), prescription-only, dispensed as an autoinjector with a label-specified maximum frequency. Compounded or research-chemical “PT-141” sold outside that pathway is not the approved product.

The approval and its safety monitoring apply only to the branded, prescribed product.

FDA approval record
For this step
No product needed
Safety

Know the documented risks

Documented trial side effects include nausea (most common), flushing, injection-site reactions, and headache; a transient blood-pressure increase is a labeled concern. Off-label or compounded use in men or outside the approved population is not FDA-evaluated for that use.

These are the trial-documented risks for the approved indication; risk outside that population has not been evaluated the same way.

FDA labeling; RECONNECT trial safety data
For this step
No product needed
What it is

Unlike PDE5 drugs such as Viagra or Cialis, which work on blood flow, PT-141 acts centrally in the brain on the melanocortin system that governs sexual desire. This page is informational: it reports what PT-141 is, what its FDA approval actually covers, and where the evidence stops. It is not instructions for use.

Why it works▼
The FDA approved Vyleesi (bremelanotide) in June 2019 specifically for hypoactive sexual desire disorder in premenopausal women, based on the RECONNECT phase 3 trial program. That is a real, Tier A approval, but the honest caveat matters: the evidence is strong only for that specific population and indication. Using PT-141 for general libido enhancement, in men, or outside the approved population is off-label and much less studied, and should not be described with the same “approved” framing. Andrew Huberman's Huberman Lab episode on peptide therapeutics confirms PT-141's FDA approval is specifically for premenopausal HSDD, matching the Tier A framing here. Compounded or research-chemical “PT-141” sold outside the approved pathway is not the approved product and carries the same purity and sourcing concerns as other gray-market peptides.
The evidence
Sources 1
Primary sources behind this page, cited straight to the source: peer-reviewed papers and reporting. Select any to view it here.
1
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (confirms PT-141/Vyleesi's FDA approval for HSDD)
Article · hubermanlab.com
Source viewer
Loading the first source…
Is this for you?
Good fit if
  • Anyone trying to understand what PT-141 or Vyleesi is actually approved for
  • Anyone who has seen PT-141 marketed for general libido enhancement and wants the approved-use boundary
  • Patients or caregivers preparing questions for a prescriber
  • Readers comparing PT-141 to unregulated “research peptide” versions
Cautions
  • Educational only, not medical advice; any decision about a prescription medication belongs with a licensed prescriber.
  • The FDA approval covers hypoactive sexual desire disorder in premenopausal women specifically, not general use.
  • Compounded or research-chemical “PT-141” sold outside the approved pathway carries the same purity and sourcing concerns as other gray-market peptides.
Common questions
Is PT-141 FDA-approved?▾
Yes, as Vyleesi, but only for hypoactive sexual desire disorder (HSDD) in premenopausal women, based on the RECONNECT phase 3 trial program. Use outside that population and indication is off-label.
Can men use PT-141?▾
PT-141 is not FDA-approved for use in men; any such use is off-label and has not gone through the same trial evaluation as the approved indication.
Is research-chemical PT-141 the same as Vyleesi?▾
No. Vyleesi is the FDA-approved, prescription autoinjector. Compounded or research-chemical “PT-141” sold outside that pathway is not the approved product and carries unregulated-sourcing risk.
Related protocols
⚠️
Peptides
Melanotan II: The Safety Risks and Legal Status
Based on the work of YourProtocol
Get the next protocol first

New expert protocols and evidence updates, cited to the source. No spam; unsubscribe anytime.

Also good for: Optimize Hormones

Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.

PT-141 / Bremelanotide: Evidence and Safety
Read the evidence
Read it